Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04706598
What this trial is testing

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Who this might be right for
Urinary Bladder NeoplasmsImmunotherapy
Fudan University 25
Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Large-scale testing (Phase 3)Active Not RecruitingNCT05943106
What this trial is testing

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Who this might be right for
Non-Muscle- Invasive Bladder Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)UnknownNCT05418309
What this trial is testing

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

Who this might be right for
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63
Post-approval studies (Phase 4)Looking for participantsNCT05962541
What this trial is testing

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Who this might be right for
Non-muscle-invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial CarcinomaHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza 327
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07625527
What this trial is testing

Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerNon Muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital 120
Not applicableUnknownNCT06324058
What this trial is testing

Cryoablation Versus BCG Instillation Therapy for High-risk NMIBC

Who this might be right for
Bladder Cancer
Huashan Hospital 190
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07100184
What this trial is testing

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

Who this might be right for
HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT
Peking University First Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06567743
What this trial is testing

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Who this might be right for
High-Risk Non-Muscle-Invasive Bladder Cancer
CG Oncology, Inc. 325